Abstract 1590P
Background
The LEGACy project aims to improve personalized medicine for gastric cancer in EU and LATAM populations. A hospital-based registry was implemented to compare these populations as a potential tool to plan prevention and treatment strategies providing real-world data.
Methods
A retrospective observational cohort design was used. Survival estimates were determined using actuarial Kaplan-Meier curves. Comparison was performed with the loge-rank test, and differences were considered statistically significant for P values .05.
Results
A total of 689 patients diagnosed with GC from 11/2018 to 04/2021 were included. Country and clinical characteristics are shown in the table. Both cohorts had the body as the most common site reported (34.4% for EU and 51% for LATAM). The most used method for staging was computed tomography for both cohorts, but 6.9% of the LATAM population had a PET/TC instead. The staging at diagnose for LATAM was lower than for the EU population (2.8% and 17.4% respectively). Intestinal histological subtype was the most common (41.9% and 46.3% reported by EU and LATAM), while diffuse subtype was 44.9% for LATAM and 21.3% for EU population. Among patients tested for HER2, 12.5% were positive in the EU cohort and 13.8% in the LATAM cohort. For both cohorts, the most common site of HER2 positive was the GOJ. Surgery was reported in 43.4% of EU population and 48.9% in the LATAM cohort. Systemic treatment with curative intention was indicated in 50.7% in the EU cohort and 46.4% of the LATAM cohort. The most frequent scheme indicated was platinum-based (42.6% and 84.8% for EU and LATAM). Considering both cohorts only 14.4% of the patients got a 2° line of treatment and 3% of the patients received a 3° line. After using cox regression analysis, no difference in overall survival was reported, with a median of 10.9 months.
Table: 1590P
Characteristic | EU Cohort (n: 407) | LATAM Cohort (n: 282) |
Age - Median y [IQR] | 70.50 [61.00, 78.00] | 63.00 [53.00, 71.00] |
Sex - n (%) | ||
Male | 243 (59.9%) | 166 (59.1%) |
Country - n | ||
Argentine | 67 | |
Chile | 112 | |
Mexico | 70 | |
Netherlands | 159 | |
Paraguay | 31 | |
Portugal | 124 | |
Spain | 121 | |
ECOG n (%) | ||
0 | 45 (21.1%) | 61 (27.7%) |
1 | 110 (51.6%) | 116 (52.7%) |
≥2 | 47 (22.1%) | 43 (19.9%) |
Conclusions
Although the limitations of hospital-based registry analysis, this study have provided valuable insights into clinical characteristics and treatment approaches of EU and LATAM populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Union’s Horizon 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22